Interpace Diagnostics: Up on deal to develop thyroid-related diagnostic products

Interpace Biosciences

18/07/2019 12:33

** Cancer diagnostics co's shares  IDXG.O  rise 6.3% to
$0.83 premarket on deal with a division of Predictive Oncology
 POAI.O 
    ** IDXG is among the top pct gainers across U.S. exchanges
before the bell
    ** As per the deal, the companies expect to develop products
to diagnose and assess risk for thyroid cancer
    ** Helomics, Predictive Oncology's division, will also build
a model using IDXG's existing clinical data to identify
druggable targets to treat thyroid cancers  urn:newsml:reuters.com:*:nGNX6tgZDz
    ** Stock has fallen nearly 22% this year 

 (Reporting by Amy Caren Daniel in Bengaluru)
 ((Reuters Messaging:
Amy.CarenDaniel.thomsonreuters.com@reuters.net))